Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

diaDexus gets US patent for heart disease test:

This article was originally published in Clinica

Executive Summary

diaDexus has been issued with a US patent covering its blood test for a patient's susceptibility to atherosclerosis. The immunoassay-based test measures the levels of Lp-PLA2, a risk factor for coronary heart disease (see Clinica No 931, p 19). The Santa Clara, California company says that Lp-PLA2 is independent of other known risk factors, including low-density lipoprotein cholesterol and C-reactive protein. The patent was licensed from GlaxoSmithKline, which discovered that Lp-PLA2 was associated with atherosclerotic plaque.

You may also be interested in...



Celltrion Makes Progress On Coronavirus Treatment

Celltrion has accelerated the development of its antiviral treatment for COVID-19 and aims to launch a rapid self-testing kit that could provide results within 15-20 minutes. The Korean firm also plans to develop a ‘super antibody’ to prepare for potential future pandemic situations.

Spain Lists Certain OTCs As 'Essential' In Fight Against COVID-19

Paracetamol, acetylcysteine and loperamide among list of OTC drugs deemed "essential" by Spain in the fight against coronavirus.

Mylan And Lupin Get EU Etanercept Nod

Mylan, in partnership with Indian firm Lupin, will be looking to rival Biogen and Sandoz by introducing an etanercept biosimilar in European markets following a positive opinion by the EMA’s CHMP on Mylan's application.

Topics

UsernamePublicRestriction

Register

MT070561

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel